Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment

In an Investigator-Sponsored Trial at Memorial Sloan Kettering, 80% of SER-155 recipients achieved an immunosuppressive-free clinical response of diarrhea (a primary irEC symptom) by Day 15. This suggests a potentially effective safety/efficacy profile by avoiding immunosuppressive therapy for responders. The result is likely positive for ongoing development sentiment, though it is confined to an IST.

Analysis

In an Investigator-Sponsored Trial at Memorial Sloan Kettering, 80% of SER-155 recipients achieved an immunosuppressive-free clinical response of diarrhea (a primary irEC symptom) by Day 15. This suggests a potentially effective safety/efficacy profile by avoiding immunosuppressive therapy for responders. The result is likely positive for ongoing development sentiment, though it is confined to an IST.